TG Therapeutics financials
$56.190.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $240.3M | $204.9M | $192.6M | $161.7M | $141.1M | $120.9M | $108.2M | $83.9M | $73.5M | $63.5M | $44.0M | $165.8M |
| Gross profit | $199.1M | $171.4M | $154.4M | $133.6M | $122.2M | $105.3M | $92.8M | $74.5M | $65.2M | $58.0M | $36.1M | $162.3M |
| Gross margin | 82.9% | 83.6% | 80.2% | 82.6% | 86.6% | 87.1% | 85.8% | 88.9% | 88.7% | 91.4% | 82.1% | 97.9% |
| Operating income | $21.7M | $34.8M | $50.5M | $29.4M | $34.8M | $8.6M | $29.9M | $12.4M | $8.8M | -$9.3M | -$12.5M | $114.8M |
| Net income | $7.8M | $19.8M | $23.0M | $390.9M | $28.2M | $5.1M | $23.3M | $3.9M | $6.9M | -$10.7M | -$14.4M | $113.9M |
| Net margin | 3.2% | 9.7% | 12.0% | 241.7% | 20.0% | 4.2% | 21.6% | 4.6% | 9.4% | −16.9% | −32.8% | 68.7% |
| Diluted EPS | $0.05 | $0.12 | $0.14 | $2.43 | $0.17 | $0.03 | $0.13 | $0.02 | $0.04 | $-0.07 | $-0.09 | $0.73 |
| EBITDA | $21.7M | $34.8M | $50.4M | $29.5M | $34.9M | $8.6M | $29.8M | $12.6M | $8.8M | -$9.2M | -$12.5M | $114.9M |
| Operating cash flow | $39.3M | -$17.9M | $19.7M | -$23.2M | $7.4M | -$28.7M | -$25.6M | -$12.2M | $5.5M | -$8.2M | -$13.2M | $83.7M |
| Free cash flow | $39.0M | -$17.9M | $19.6M | -$23.2M | $7.4M | -$28.7M | -$25.7M | -$12.2M | $5.5M | -$8.2M | -$13.2M | $83.7M |
| Diluted shares | 157.3M | 160.1M | 159.3M | 161.0M | 162.6M | 162.8M | 175.0M | 160.7M | 159.4M | 146.2M | 156.3M | 155.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $482.6M | $442.2M | $79.1M | $74.1M | $129.1M | $132.1M |
| Short-term investments | $69.7M | $72.2M | $62.8M | $57.5M | $122.7M | $144.1M |
| Total debt | $745.4M | $745.1M | $245.6M | $245.3M | $245.0M | $244.7M |
| Total assets | $1.64B | $1.53B | $1.06B | $1.03B | $702.6M | $656.7M |
| Total liabilities | $1.04B | $945.7M | $415.2M | $417.8M | $426.2M | $419.4M |
| Shareholders' equity | $604.1M | $583.1M | $648.0M | $607.2M | $276.4M | $237.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology